This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ng, V. L.
Right arrow Articles by Hadley, W. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ng, V. L.
Right arrow Articles by Hadley, W. K.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, 07 1997, 401-418, Vol 10, No. 3
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Extrapulmonary pneumocystosis

VL Ng, DM Yajko and WK Hadley
Department of Laboratory Medicine, University of California San Francisco, USA. ng@pangloss.ucsf.edu

Extrapulmonary pneumocystosis is an exceedingly rare complication of Pneumocystis carinii pneumonia (PCP). Prior to the advent of the human immunodeficiency virus type 1 (HIV-1) epidemic, only 16 cases of extrapulmonary pneumocystosis in individuals who were immunocompromised by a variety of underlying diseases had been reported. Since the beginning of the HIV-1 and related PCP epidemic, at least 90 cases of extrapulmonary pneumocystosis have been reported. This review briefly presents a history of the discovery of P. carinii and its recognition as a human pathogen, the controversy regarding its taxonomy, and the epidemiology of this organism. A more detailed analysis of the incidence of extrapulmonary pneumocystosis in HIV-1-infected individuals and its occurrence despite widespread prophylaxis for PCP with either aerosolized pentamidine or systemic dapsone-trimethoprim is presented. The clinical features of published cases of extrapulmonary pneumocystosis in non-HIV-1-infected individuals are summarized and contrasted with those in HIV-1 infected individuals. The diagnosis of extrapulmonary pneumocystosis is discussed, and because clinical microbiologists and pathologists are the key individuals in establishing the diagnosis, the characteristic microscopic morphology of P. carinii as its appears when stained with a variety of stains is presented and reviewed. The review concludes with a brief discussion of treatments for extrapulmonary pneumocystosis.


This article has been cited by other articles:

  • Kovacs, J. A., Masur, H. (2009). Evolving Health Effects of Pneumocystis: One Hundred Years of Progress in Diagnosis and Treatment. JAMA 301: 2578-2585 [Abstract] [Full Text]  
  • Lionakis, M. S., Samonis, G., Kontoyiannis, D. P. (2008). Endocrine and Metabolic Manifestations of Invasive Fungal Infections and Systemic Antifungal Treatment. Mayo Clin Proc. 83: 1046-1060 [Abstract] [Full Text]  
  • Icenhour, C. R., Rebholz, S. L., Collins, M. S., Cushion, M. T. (2002). Early Acquisition of Pneumocystis carinii in Neonatal Rats as Evidenced by PCR and Oral Swabs. Eukaryot Cell 1: 414-419 [Abstract] [Full Text]  
  • Kovacs, J. A., Gill, V. J., Meshnick, S., Masur, H. (2001). New Insights Into Transmission, Diagnosis, and Drug Treatment of Pneumocystis carinii Pneumonia. JAMA 286: 2450-2460 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»